Loading stock data…
Autolus Therapeutics plc (AUTL)
$2.11-0.13 (-5.80%)
After Hours$2.16+0.05 (+2.37%)· Last close Sep 8
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Autolus Therapeutics plc in the Healthcare sector is trading at $2.11 with a market capitalization of $431M. Wall Street consensus targets $8.72 (8 analysts), implying a +313.5% move over the next 12 months. The stock is currently 18% below its 52-week high of $2.58, remaining 29.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +313.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.22M↑ | $24.29M↑ | $21.19M↑ | $20.92M↑ | $8.98M |
| Gross Profit | $1.65M↑ | -$1.04M↑ | -$7.45M↓ | -$3.52M↑ | -$8.97M |
| Operating Income | -$59.51M↑ | -$72.47M↓ | -$71.62M↓ | -$61.22M↑ | -$65.24M |
| Net Income | -$71.60M↑ | -$90.33M↓ | -$79.12M↓ | -$47.92M↑ | -$70.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consist...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$431.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-265.53%
Volume
Today's trading volume
2.57M
Recent News
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
European equities traded in the US as American depositary receipts were marginally higher late Frida
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading
European equities traded in the US as American depositary receipts started the week slightly lower l
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending higher late Friday